Journal of Reproductive Immunology
Volume 84, Issue 2 , Page 206 , March 2010

Statins for the treatment of obstetric complications in antiphospholipid syndrome?

  • Michael D. Lockshin

      Affiliations

    • Barbara Volcker Center for Women and Rheumatic Diseases, New York, United States
    • Mary Kirkland Center for Lupus Research at the Hospital for Special Surgery, New York, United States
    • Medicine and Obstetrics-Gynecology, Joan and Sanford Weill College of Medicine, New York, United States
  • Silvia S. Pierangeli

      Affiliations

    • Corresponding Author InformationCorresponding author at: Brackenridge Hall 2.108, 301 University Boulevard, Galveston, TX 77555-0883, United States. Tel.: +1 409 772 0222; fax: +1 409 772 0223.

Received 11 October 2009

References 

  1. Ding J, Jiang D, Kurczy M, Nalepka J, Dudley B, Merkel EI, et al. Inhibition of HMG CoA reductase reveals an unexpected role for cholesterol during PGC migration in the mouse. BMC Dev. Biol. 2008;8:120
  2. Forbes K, Hurst LM, Aplin JD, Westwood M, Gibson JM. Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable. J. Cell. Mol. Med. 2008;12:2295–2296
  3. Kenis I, Tartakover-Matalon S, Cherepnin N, Drucker L, Fishman A, Pomeranz M, et al. Simvastatin has deleterious effects on human first trimester placental explants. Hum. Reprod. 2005;20:2866–2872
  4. Ponce J, de La Ossa NP, Hurtado O, MIllan M, Arenillas JF, Davalos A, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol mediated effect in neuroprotection. Stroke. 2008;39:1269–1275
  5. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham MK, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res. A Clin. Mol. Theratol. 2005;73:888–896

PII: S0165-0378(10)00011-2

doi: 10.1016/j.jri.2009.11.007

Journal of Reproductive Immunology
Volume 84, Issue 2 , Page 206 , March 2010

Article Tools